HLA-DR3

Jump to: navigation, search
Illustration of an HLA-DR (Human MHC class II) antigen receptor with bound antigen
major histocompatibility complex, class II, DR3
Haplotypes groups DRA*01:DRB1*0301 DRA*01:DRB1*0302 DRA*01:DRB1*0303 DRA*01:DRB1*0304
Structure (See HLA-DR)
Identifiers
alpha *0101
Symbol(s) HLA-DRA
EBI-HLA DRA*0101
Identifiers
beta 1 *0301 *0301 *0302 *0303 *0304
Symbol(s) HLA-DRB1
EBI-HLA DRB1*0301
EBI-HLA DRB1*0302
EBI-HLA DRB1*0303
EBI-HLA DRB1*0304
EBI-HLA DRB1*0305
Shared data
Locus chr.6 6p21.31

HLA-DR3 is composed to the HLA-DR17 and HLA-DR18 split 'antigens' serotypes.


Serology

DR17 and DR3 recognition of some DRB1*03 alleles[1]
DRB1* DR3 DR17 DR18 Sample
allele % % % size (N)
0301 33 64 0 9698
0302 24 3 66 317
0303 40 60 5
0304 60 20 5
0307 >50 1

Some DR3 also react with HLA-DR17 and/or HLA-DR18. The DRB1*0304 primarily reacts with DR3. The serotypes of *0305, *0306, *0308 to *0331 are unknown.

Disease associations

By serotype

HLA-DR3 is associated with early-age onset myasthenia gravis, primary sclerosing cholangitis,[2] and opportunistic infections in AIDS[3], but lowered risk for cancers[4].

By allele

DRB1*0301 (see HLA-DR17)

DRB1*0302 (See HLA-DR18)

DRB1*0304 is associated it graves disease[5]

By haplotypes

DR3 and/or DQ2 is associated with Moreen's ulceration[6], "bout onset" multiple schlerosis[7], Grave's disease[8] and systemic lupus erythematosus[9]

DR3-DQ2 linkage is associated with coeliac disease, dermatitis herpetiformis, juvenile diabetes. DR3-DR2 is the serological marker for HLA-DQ2.5cis isoform. Although it cannot identify the alpha ".5" chain of HLA DQ, DQA1*0501 gene is almost always found within the DR3-DQ2 haplotype Eurasia (however is older studies DQA1*0505 is commonly confused with DQA1*0501)
PMID 10777105

Genetic linkage

DR3 is genetically linked to HLA-DR52, DRB3*0202 allele, and HLA-DQ2 (DQ2.5).

References

  1. derived from IMGT/HLA
  2. Wiencke K, Karlsen TH, Boberg KM; et al. (2007). "Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes". Tissue Antigens. 69 (2): 161–9. doi:10.1111/j.1399-0039.2006.00738.x. PMID 17257319.
  3. Pollack MS, Gold J, Metroka CE, Safai B, Dupont B (1984). "HLA-A,B,C and DR antigen frequencies in acquired immunodeficiency syndrome (AIDS) patients with opportunistic infections". Hum. Immunol. 11 (2): 99–103. PMID 6333416.
  4. Mann DL, Murray C, O'Donnell M, Blattner WA, Goedert JJ (1990). "HLA antigen frequencies in HIV-1-related Kaposi's sarcoma". J. Acquir. Immune Defic. Syndr. 3 Suppl 1: S51–5. PMID 2395088.
  5. . PMID 10468973. Missing or empty |title= (help)
  6. Taylor C, Smith S, Morgan C, Stephenson S, Key T, Srinivasan M, Cunningham E, Watson P (2000). "HLA and Mooren's ulceration". Br J Ophthalmol. 84 (1): 72–5. PMID 10611103.
  7. Weinshenker B, Santrach P, Bissonet A, McDonnell S, Schaid D, Moore S, Rodriguez M (1998). "Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study". Neurology. 51 (3): 742–7. PMID 9748020.
  8. Ratanachaiyavong S, Lloyd L, Darke C, McGregor A (1993). "MHC-extended haplotypes in families of patients with Graves' disease". Hum Immunol. 36 (2): 99–111. PMID 8096501.
  9. Tjernström F, Hellmer G, Nived O, Truedsson L, Sturfelt G (1999). "Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus". Lupus. 8 (2): 103–8. PMID 10192503.